Failure of the Mycobacterium bovis BCG vaccine: Some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis

Infection and Immunity

Volumn 70, Issue 2, 2002, Pages 672-678

  Brandt, Lise ^a   Cunha, Joana Feino ^a   Olsen, Anja Weinreich ^a   Chilima, Ben ^a   Hirsch, Penny ^a   Appelberg, Rui ^a   Andersen, Peter ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BCG VACCINATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNITY; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION;

ACYLTRANSFERASES; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BCG VACCINE; CELLS, CULTURED; FEMALE; LYMPHOCYTES; MALAWI; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM BOVIS; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM SCROFULACEUM; SPLEEN; TUBERCULOSIS, PULMONARY;

EID: 0036153758     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.2.672-678.2002     Document Type: Article

References (44)

1. Does the protective effect of neonatal BCG correlate with vaccineinduced tuberculin reaction?
2. Interspecies reactivity of five monoclonal antibodies to Mycobacterium tuberculosis as examined by immunoblotting and enzyme-linked immunosorbent assay
3. Host responses and antigens involved in protective immunity to Mycobacterium tuberculosis
4. Tuberculosis prevention trial
5. ESAT-6 subunit vaccination against Mycobacterium tuberculosis
6. Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis
7. The effect of oral Mycobacterium vaccae on subsequent responses of mice to BCG sensitization
8. The BCG controversy. A methodological and statistical reappraisal
9. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: Meta-analyses of the published literature
10. Immunogenicity of various mycobacteria and the corresponding levels of cross-protection developed between species
11. Control of the Bcg gene of early resistance in mice to infections with BCG substrains and atypical mycobacteria
12. Tuberculosis vaccines: Developmental work and the future
13. Efficacy of bacillus Calmette-Guérin and isoniazid-resistant bacillus Calmette-Guérin with and without isoniazid chemoprophylaxis from day of vaccination
14. Infection with Mycobacterium avium-intracellulare and the protective effects of Bacille Calmette-Guerin
15. The BCG story: Lessons from the past and implications for the future
16. Variation in protection by BCG: Implications of and for heterologous immunity
17. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection
18. B-cell epitopes and quantification of the ESAT-6 protein of Mycobacterium tuberculosis
19. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life
20. Immune response & modulation of immune response induced in the guinea-pigs by Mycobacterium avium complex (MAC) & M. fortuitum complex isolates from different sources in the South Indian BCG trial area
21. Isolation and identification of environmental mycobacteria in the Mycobacterium bovis BCG trial area of South India
22. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi
23. Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains
24. Evaluation of the effectiveness of BCG vaccination using the case-control method in Buenos Aires
25. Importance of thymus-derived lymphocytes in cell-mediated immunity to infection
26. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6
27. Progress in the development of new vaccines against tuberculosis
28. T cell response to Mycobacterium tuberculosis
29. T lymphocytes mediating protection and cellular cytolysis during the course of Mycobacterium tuberculosis infection. Evidence for different kinetics and recognition of a wide spectrum of protein antigens
30. Lack of evidence for a reduction in the efficacy of subcutaneous BCG vaccination in mice infected with nontuberculous mycobacteria
31. Analysis of T cells recruited during delayed-type hypersensitivity to purified protein derivative (PPD) versus challenge with tuberculosis infection
32. BCG vaccination and tuberculin allergy
33. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis
34. The effect of two distinct forms of cell-mediated response to mycobacteria on the protective efficacy of BCG
35. The protective effects of BCG vaccination against tuberculosis
36. How environmental mycobacteria may predetermine the protective efficacy of BCG
37. Does the efficacy of BCG decline with time since vaccination?
38. Research on BCG vaccination
39. Studies on the effect of isoniazid upon the antituberculous immunity induced by BCG vaccination
40. The case for BCG
41. Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention, Chennai
42. Mixed mycobacterial infections
43. W.H.O. news and activities
44. Current tuberculosis vaccine development